Adam Welch, PharmD, MBA, FAPhA, leads a discussion surrounding payer considerations for RSV vaccinations in children.
Respiratory Syncytial Virus (RSV) in Infants and Children
Medical experts discuss current obstacles facing ideal respiratory syncytial virus (RSV) treatment strategies in children.
Long-term effects of pediatric RSV diagnosis are explored.
The panel highlights the current standards of care and strategies for treating children with RSV.
Revolutionary advancements in monoclonal antibodies are considered for prevention of RSV.
Preemptive treatment strategies for pediatric RSV are discussed by key opinion leaders.
RSV diagnosis can lead to an array of financial complications.
In their closing thoughts the panelists discuss reimbursement-related considerations surrounding mAbs.
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
3
Online GLP-1 Sellers Often Skip Clinician Oversight
4
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
5